BrainsWay Ltd. (BRSYF) Stock Analysis

BrainsWay Ltd. (BRSYF) Healthcare & Pipeline Overview

BrainsWay Ltd. is a Jerusalem-based medical device company specializing in noninvasive neurostimulation treatments. Its Deep Transcranial Magnetic Stimulation (Deep TMS) platform addresses a wide range of mental health and neurological disorders globally, serving psychiatric practices and medical centers with advanced therapeutic solutions.

What Is the Investment Thesis for BRSYF?

BrainsWay Ltd. presents a unique investment profile centered on its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology, addressing a significant and growing market for noninvasive mental health and neurological treatments. The company's strong gross margin of 75.5% and profit margin of 15.6% underscore the economic efficiency and profitability of its core product. With a market capitalization of $607M, BrainsWay operates in a specialized niche within the medical device sector. Key value drivers include the expanding applications of its Deep TMS platform, which currently treats major depressive disorders, OCD, and smoking addiction, with potential for further indications like Alzheimer's and Parkinson's. The non-invasive nature of its technology positions it favorably against traditional pharmacological or more invasive interventions. While the debt-to-equity ratio of 8.85 indicates a reliance on debt, the 12.6% Return on Equity suggests effective capital utilization. Future growth is anticipated from broader market adoption in existing geographies and potential expansion into new international markets, driven by increasing awareness and demand for advanced neurostimulation therapies.

Based on FMP financials and quantitative analysis

BRSYF Key Highlights

Market Capitalization: $607M, positioning BrainsWay as a small-cap player in the medical device industry.

• Gross Margin: 75.5%, indicating robust profitability on its Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
• Profit Margin: 15.6%, demonstrating efficient operational management and strong bottom-line performance.
• Return on Equity (ROE): 12.6%, reflecting the company's ability to generate profit from shareholders' equity.
• Debt-to-Equity (D/E): 8.85, suggesting a significant reliance on debt financing relative to equity.

Who Are BRSYF's Competitors?

BRSYF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BRSYF's Key Strengths?

Proprietary Deep TMS technology with broad therapeutic applications.

• Strong gross margin of 75.5% and profit margin of 15.6%.
• Established international presence in key markets like the US and Europe.
• Addresses a wide range of mental health and neurological disorders.
• Non-invasive nature of treatment appeals to patients and clinicians.

What Are BRSYF's Weaknesses?

Relatively high Debt-to-Equity ratio of 8.85.

• Market capitalization of $607M indicates a smaller company size.
• Reliance on regulatory approvals for new indications and market expansion.
• Operating in a highly specialized and competitive medical device niche.
• Disclosure status on OTC market is 'Unknown', potentially limiting investor confidence.

What Could Drive BRSYF Stock Higher?

BRSYF catalyst: Regulatory Approval for New Indications: Securing additional regulatory clearances (e.g., FDA, CE Mark) for Deep TMS to treat conditions like Alzheimer's disease, Parkinson's disease, or PTSD could significantly expand BrainsWay's addressable market and revenue potential.

• Such approvals are typically preceded by successful clinical trial results.
• Expansion of Geographic Reach: Continued efforts to penetrate new international markets beyond the current presence in the US, Europe, and Israel. Establishing new distribution channels and securing local regulatory approvals in untapped regions could drive sales growth.
• Publication of Positive Clinical Trial Data: Release of favorable results from ongoing or completed clinical trials for new Deep TMS applications could bolster scientific credibility, increase physician adoption, and support future regulatory submissions.
• Increased Market Adoption of Deep TMS: Growing awareness and acceptance among psychiatrists and medical centers of Deep TMS as an effective, non-invasive treatment option for existing indications like MDD and OCD, leading to higher utilization rates and device sales.

What Are the Key Risks for BRSYF?

Rich valuation — a P/E of 57.72 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Regulatory Hurdles and Delays: The medical device industry is highly regulated. Delays or failures in obtaining regulatory approvals for new indications or market expansions could impede growth and increase development costs.
• Intense Competition: BrainsWay operates in a competitive landscape with other TMS device manufacturers and companies developing alternative neurostimulation therapies, potentially leading to pricing pressures or market share erosion.
• Reimbursement Challenges: Lack of adequate reimbursement coverage from insurance providers for Deep TMS treatments, especially for newer indications, could limit patient access and hinder adoption rates.
• Dependence on Key Technology: The company's business is heavily reliant on the success and continued relevance of its Deep TMS platform. Any technological obsolescence or emergence of superior alternatives could pose a significant threat.
• OTC Market Risks: As an OTC-traded company with 'Unknown' disclosure, BRSYF faces risks of lower liquidity, higher volatility, and limited access to comprehensive financial information, which can deter institutional investors.

What Are the Growth Opportunities for BRSYF?

• Expansion of Deep TMS Indications: BrainsWay's Deep TMS platform currently treats major depressive disorders, obsessive-compulsive disorders, and smoking addiction. Significant growth potential exists in securing regulatory approvals and market adoption for additional indications such as bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. Each new approved indication opens up access to vast patient populations and new revenue streams, with the global market for neurological and psychiatric disorders representing hundreds of billions of dollars. This expansion is an ongoing process, with clinical trials and regulatory submissions being key milestones over the next 3-5 years.
• Geographic Market Penetration: While BrainsWay has established a presence in the United States, Europe, and Israel, there are numerous international markets with unmet needs for advanced noninvasive neurostimulation therapies. Expanding into new regions, particularly in Asia-Pacific and Latin America, could significantly broaden the company's customer base and revenue streams. This involves navigating diverse regulatory environments and establishing distribution networks, a process that could unfold over the next 5-10 years. The global medical device market, valued at over $500 billion, offers substantial untapped opportunities for specialized technologies.
• Increased Adoption in Existing Markets: Despite current market presence, there is still considerable room for increased adoption of Deep TMS technology within existing operational geographies. Growing awareness among healthcare professionals and patients about the efficacy and non-invasive nature of Deep TMS can drive higher utilization rates in psychiatric practices and medical centers. Educational initiatives, clinical evidence dissemination, and favorable reimbursement policies are crucial for accelerating this adoption over the next 2-7 years. The increasing prevalence of mental health disorders globally underscores the ongoing demand for effective treatment modalities.
• Technological Advancements and Next-Generation Devices: Continuous research and development to enhance the Deep TMS platform's efficacy, user-friendliness, and cost-effectiveness presents a significant growth opportunity. Innovations could include more personalized treatment protocols, integration with digital health platforms, or the development of more compact and versatile devices. Such advancements could maintain BrainsWay's competitive edge and attract new customers. This ongoing R&D cycle typically yields new product iterations or enhancements every 2-5 years, ensuring the technology remains at the forefront of neurostimulation.
• Strategic Partnerships and Collaborations: Forming strategic alliances with leading research institutions, pharmaceutical companies, or large healthcare systems could accelerate product development, expand market reach, and enhance clinical validation. Collaborations could focus on joint research for new indications, co-marketing efforts, or integrating Deep TMS into broader treatment pathways. These partnerships can provide access to new capital, expertise, and distribution channels, potentially leading to significant growth within a 3-7 year timeframe. Such alliances are common in the medical device sector to leverage complementary strengths.

What Threats Does BRSYF Face?

• Intense competition from other TMS device manufacturers and alternative therapies.
• Potential for adverse regulatory changes or delays in approvals.
• Reimbursement challenges for new or existing indications.
• Technological obsolescence or emergence of superior treatment modalities.
• Economic downturns impacting healthcare spending and capital equipment purchases.

What Are BRSYF's Competitive Advantages?

• Proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology, offering unique brain penetration capabilities.
• Broad range of FDA-cleared and CE-marked indications for mental health and neurological disorders.
• Established international presence and distribution network in key healthcare markets.
• Clinical evidence and research supporting the efficacy of its non-invasive treatment platform.
• Specialized expertise in neurostimulation, built over two decades since its founding in 2003.

What Does BRSYF Do?

BrainsWay Ltd., founded in 2003 and headquartered in Jerusalem, Israel, is a pioneering medical device company dedicated to the development and commercialization of noninvasive neurostimulation treatments. The company's flagship offering is its Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology, designed to address a broad spectrum of mental health and neurological conditions. This innovative technology provides a non-pharmacological and non-invasive therapeutic option for patients and clinicians alike. BrainsWay's Deep TMS has been applied to treat major depressive disorders, including anxious depression, and obsessive-compulsive disorders, demonstrating its utility in complex psychiatric conditions. Beyond these, the technology is also utilized or being explored for smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease, showcasing its versatile therapeutic potential across various neurological and psychiatric indications. The company primarily serves a professional clientele, including doctors, hospitals, and medical centers specializing in psychiatry and neurology. BrainsWay operates on an international scale, with its products sold in key markets such as the United States, Europe, Israel, and other international regions, establishing a global footprint in the advanced medical device sector. With 120 employees, BrainsWay continues to focus on advancing its Deep TMS technology to meet the evolving needs of mental health and neurological care.

What Products and Services Does BRSYF Offer?

• Develops and sells noninvasive neurostimulation treatments for mental health and neurological disorders.
• Offers Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
• Treats major depressive disorders, including anxious depression, and obsessive-compulsive disorders.
• Addresses smoking addiction, bipolar disorders, and post-traumatic stress disorders.
• Explores applications for schizophrenia, Alzheimer's disease, autism, and chronic pain.
• Investigates use in multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease.
• Serves doctors, hospitals, and medical centers, primarily in psychiatry.
• Operates in the United States, Europe, Israel, and other international markets.

How Does BRSYF Make Money?

• Sells Deep Transcranial Magnetic Stimulation (Deep TMS) platform devices directly to healthcare providers.
• Generates revenue from the sale of capital equipment to doctors, hospitals, and medical centers.
• Potentially earns recurring revenue from disposable components or service contracts associated with the Deep TMS systems.
• Focuses on a business-to-business (B2B) model, targeting psychiatric and neurological clinics.
• Leverages international distribution channels to reach markets in North America, Europe, and the Middle East.

What Industry Does BRSYF Operate In?

BrainsWay Ltd. operates within the dynamic and growing Medical Devices industry, specifically focusing on neurostimulation treatments. This sector is characterized by continuous innovation, stringent regulatory oversight, and a high demand for non-invasive therapeutic options for neurological and psychiatric disorders. The global market for neurostimulation devices is expanding, driven by the increasing prevalence of mental health conditions, neurological diseases, and a preference for non-pharmacological interventions. BrainsWay's Deep TMS technology positions it within the transcranial magnetic stimulation (TMS) segment, a rapidly evolving area. The competitive landscape includes other TMS device manufacturers and companies developing alternative non-invasive brain stimulation techniques. BrainsWay differentiates itself through its proprietary Deep TMS technology, which offers broader and deeper brain stimulation compared to conventional TMS, potentially allowing for treatment of a wider array of conditions. The company's focus on serving doctors, hospitals, and medical centers aligns with the institutional nature of this specialized market.

Who Are BRSYF's Key Customers?

• Psychiatrists and mental health clinics seeking non-invasive treatment options.
• Hospitals and medical centers with neurology and psychiatry departments.
• Research institutions exploring advanced neurostimulation therapies.
• Private practices and specialized treatment centers for addiction and neurological conditions.
• Healthcare providers in the United States, Europe, Israel, and other international regions.

Company Profile

BrainsWay Ltd. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Jerusalem, IL. The company is led by CEO Hadar Levy. BRSYF has traded publicly since 2011.

BrainsWay Ltd. Financial Trajectory

BrainsWay Ltd. (BRSYF) reported $17.0M in revenue for Jun 2026, reflecting 9.5% growth compared to the prior quarter. The company recorded net income of $2.7M, with diluted EPS of $0.07. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, BRSYF averaged $0.06 in diluted EPS.

How BrainsWay Ltd. Is Valued

BrainsWay Ltd. carries a market capitalization of $607M, placing it in the small-cap category.

Return on equity for BrainsWay Ltd. stands at 12.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.5%, showing how much profit it generates from its asset base. BRSYF trades at a trailing price-to-earnings ratio of 57.72, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 1.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.6%, the inverse of the P/E and a quick read on earnings relative to price.

BrainsWay Ltd.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.87 places it in the safe zone, indicating low near-term bankruptcy risk.

BrainsWay Ltd. has beaten Wall Street's EPS estimate in 3 of its last 5 reported quarters — more hits than misses. Reported results have landed about 69.7% above estimates on average.

Wall Street analysts project BrainsWay Ltd. revenue of about $69.2M for fiscal 2026, with EPS near $0.00. The estimate reflects 3 contributing analysts.

BRSYF Financials

BRSYF Latest News

BRSYF Analyst Consensus

BRSYF MoonshotScore

BRSYF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources